| Identification | Back Directory | [Name]
mulberroside A | [CAS]
102841-42-9 | [Synonyms]
mulberroside A
Mulberroside A, 98%, from Morus alba L.
2,5'-Dihydroxy-4,3'-bis(β-D-glucopyranosyloxy)-trans-stilbene
2,5'-Dihydroxy-4,3'-bis(beta-D-glucopyranosyloxy)-trans-stilbene
b-D-Glucopyranoside,3-[(1E)-2-[4-(b-D-glucopyranosyloxy)-2-hydroxyphenyl]ethenyl]-5-hydroxyphenyl
β-D-Glucopyranoside, 3-[(1E)-2-[4-(β-D-glucopyranosyloxy)-2-hydroxyphenyl]ethenyl]-5-hydroxyphenyl
2-(4-hydroxy-1,3-thiazol-3-ium-3-yl)ethyl [2-(octadecylcarbamoyloxymethyl)oxolan-2-yl]methyl phosphate
beta-D-Glucopyranoside 3-[(1E)-2-[4-(beta-D-glucopyranosyloxy)-2-hydroxyphenyl]ethenyl]-5-hydroxyphenyl | [Molecular Formula]
C26H32O14 | [MDL Number]
MFCD16294844 | [MOL File]
102841-42-9.mol | [Molecular Weight]
568.52 |
| Chemical Properties | Back Directory | [Melting point ]
235-236o C | [Boiling point ]
954.7±65.0 °C(Predicted) | [density ]
1.654 | [Fp ]
531℃ | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly, Sonicated), Methanol (Slightly) | [form ]
Solid | [pka]
9.03±0.40(Predicted) | [color ]
White to Off-White | [InChIKey]
HPSWAEGGWLOOKT-WVRADKAPNA-N | [SMILES]
O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC=C(/C=C/C2C=C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C(O)C=2)C(O)=C1 |&1:1,4,6,8,10,22,23,25,27,29,r| |
| Hazard Information | Back Directory | [Description]
Mulberroside A is isolated from the ethanol extract of Morus alba root. It has anti-tyrosinase and antioxidant activity and is widely used as an active ingredient in cosmetics. | [Uses]
Mulberroside A is a stilbenoid found in Morus alba plants. Potential metabolite for Oxyresveratrol (O861920), a natural hydroxystilbene with similar bioactivity to resveratrol. COX-1 inhibitor like resveratrol (R150000), anti-cancer agent. | [Definition]
ChEBI: Cis-Mulberroside A is a glycoside and a stilbenoid. | [in vivo]
Mulberroside A (10, 20, and 40 mg/kg) decreases serum uric acid levels and increases urinary urate excretion and fractional excretion of uric acid in hyperuricemic micem[4]. | Animal Model: | Male Kun-Ming mice (20±2 g)[4] | | Dosage: | 5, 10, 20, and 40 mg/kg; the dose volume 10 mL/kg body weight | | Administration: | Orally initiated at 9:00 a.m. | | Result: | 10, 20, and 40 mg/kg significantly increased urinary urate excretion in 24 h, resulting in a remarkable elevation of fractional excretion of uric acid (FEUA), and the highest dose completely reversed FEUA alteration of hyperuricemic mice to normal. |
| [IC 50]
IL-1β; IL-6 |
|
|